Fatty acid amide hydrolase (FAAH) is a serine hydrolase enzyme responsible of the hydrolytic degradation of N-acylethanolamine endocannabinoids, such as the Arachidonoylethanolamide (anandamide, AEA), which it has been shown to alleviate pain and inflammation (1). In particular, the anti-nociceptive and anti-inflammatory effects of AEA could be enhanced by the simultaneous block of FAAH and COX enzymes (2). For this reason, several studies have been carried out in order to develop new FAAH/COX inhibitors (2). In 1997 it was reported that the NSAID ibuprofen inhibited FAAH, although with a modest potency (3), and successively the first dual inibhitor, the amide derivative of ibuprofen with a 2-amino-3-methylpyridine side chain (Ibu-AM5) was reported (4). -5). Benzylamides and piperazinoamides analogs of Ibuprofen have been also designed as less potent FAAH inhibitors than Ibu-AM5 (5). Here, I discuss the computational studies and the structure–activity relationships leading to the design, of novel Ibuprofen amide derivatives with a higher inhibition potency of FAAH and COX, which represent novel powerful anti-nociceptive agents.

Design and pharmacological evaluation of Ibuprofen amides derivatives as dual FAAH/COX inhibitors / Moraca, F; Morgillo, Cm; Deplano, A; Novellino, E; Onnis, V; Fowler, Cj; Catalanotti, B. - (2019). (Intervento presentato al convegno 2nd International Conference on Medicinal Chemistry & Drug Design tenutosi a Barcellona nel 19-20 Agosto 2019).

Design and pharmacological evaluation of Ibuprofen amides derivatives as dual FAAH/COX inhibitors

Moraca F
Primo
;
Novellino E;Catalanotti B
Ultimo
2019

Abstract

Fatty acid amide hydrolase (FAAH) is a serine hydrolase enzyme responsible of the hydrolytic degradation of N-acylethanolamine endocannabinoids, such as the Arachidonoylethanolamide (anandamide, AEA), which it has been shown to alleviate pain and inflammation (1). In particular, the anti-nociceptive and anti-inflammatory effects of AEA could be enhanced by the simultaneous block of FAAH and COX enzymes (2). For this reason, several studies have been carried out in order to develop new FAAH/COX inhibitors (2). In 1997 it was reported that the NSAID ibuprofen inhibited FAAH, although with a modest potency (3), and successively the first dual inibhitor, the amide derivative of ibuprofen with a 2-amino-3-methylpyridine side chain (Ibu-AM5) was reported (4). -5). Benzylamides and piperazinoamides analogs of Ibuprofen have been also designed as less potent FAAH inhibitors than Ibu-AM5 (5). Here, I discuss the computational studies and the structure–activity relationships leading to the design, of novel Ibuprofen amide derivatives with a higher inhibition potency of FAAH and COX, which represent novel powerful anti-nociceptive agents.
2019
Design and pharmacological evaluation of Ibuprofen amides derivatives as dual FAAH/COX inhibitors / Moraca, F; Morgillo, Cm; Deplano, A; Novellino, E; Onnis, V; Fowler, Cj; Catalanotti, B. - (2019). (Intervento presentato al convegno 2nd International Conference on Medicinal Chemistry & Drug Design tenutosi a Barcellona nel 19-20 Agosto 2019).
File in questo prodotto:
File Dimensione Formato  
Abstract-Barcellona-2019.pdf

accesso aperto

Descrizione: Abstract
Tipologia: Abstract
Licenza: Dominio pubblico
Dimensione 149.9 kB
Formato Adobe PDF
149.9 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/821091
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact